Search Results | Blood | American Society of Hematology

1-20 of 52

2 3

Sort by

Sort Order Select

Journal Articles

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Blood (2022) 139 (15): 2338–2346.

DOI: https://doi.org/10.1182/blood.2021013526

Published: 2022

Includes: Supplemental data

Journal Articles

Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma

Blood (2022) 139 (10): 1541–1556.

DOI: https://doi.org/10.1182/blood.2021012734

Published: 2022

Includes: Supplemental data

Journal Articles

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Blood (2021) 138 (24): 2499–2513.

DOI: https://doi.org/10.1182/blood.2020010543

Published: 2021

Includes: Supplemental data

Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Blood (2021) 138 (Supplement 2): LBA-6.

DOI: https://doi.org/10.1182/blood-2021-155068

Published: 2021

Journal Articles

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Blood (2021) 138 (Supplement 1): 128.

DOI: https://doi.org/10.1182/blood-2021-148778

Published: 2021

Journal Articles

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

Franck Morschhauser, Mark Bishton, Toby A. Eyre, Emmanuel Bachy, Guillaume Cartron, Loïc Ysebaert, Sabela Bobillo, Norma C. Gutierrez, L. Elizabeth Budde, Christopher P. Fox, Andrea Knapp, Manejeh Yaqub, Michael C. Wei, Carol O'Hear, Haocheng Li, Enkhtsetseg Purev, William Townsend

Blood (2021) 138 (Supplement 1): 129.

DOI: https://doi.org/10.1182/blood-2021-145694

Published: 2021

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Tycel Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Kathryn Humphrey, David Perez-Callejo, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Emma Clark, Carmelo Carlo-Stella

Blood (2021) 138 (Supplement 1): 130.

DOI: https://doi.org/10.1182/blood-2021-148949

Published: 2021

Journal Articles

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Blood (2021) 138 (Supplement 1): 131.

DOI: https://doi.org/10.1182/blood-2021-145025

Published: 2021

Journal Articles

Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Blood (2021) 138 (Supplement 1): 2818.

DOI: https://doi.org/10.1182/blood-2021-149466

Published: 2021

Journal Articles

Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas

Blood (2021) 138 (Supplement 1): 809.

DOI: https://doi.org/10.1182/blood-2021-150034

Published: 2021

Journal Articles

Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group

Blood (2021) 138 (Supplement 1): 743.

DOI: https://doi.org/10.1182/blood-2021-148626

Published: 2021

Journal Articles

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Jean-Marie Michot, Julio C. Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo, John Kuruvilla, Antonio Pinto, Vincent Ribrag, Emmanuel Bachy, Tonia J Buchholz, Soraya Carrancio, Carla Guarinos, Fan Wu, Shaoyi Li, Poliana Patah, Michael Pourdehnad, Loretta Nastoupil

Blood (2021) 138 (Supplement 1): 3574.

DOI: https://doi.org/10.1182/blood-2021-147333

Published: 2021

Journal Articles

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Blood (2021) 138 (Supplement 1): 2417.

DOI: https://doi.org/10.1182/blood-2021-148218

Published: 2021

Journal Articles

Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Blood (2021) 138 (Supplement 1): 1387.

DOI: https://doi.org/10.1182/blood-2021-150478

Published: 2021

Journal Articles

Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry

Blood (2021) 138 (Supplement 1): 885.

DOI: https://doi.org/10.1182/blood-2021-150994

Published: 2021

Journal Articles

Single-Agent Ibrutinib Versus Real-World (RW) Treatments for Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Adjusted Comparison of Resonate-2™ with the Cllear and Lyon-Sud Rw Databases

Michael Doubek, Mudr. Lukas Smolej, Martin Šimkovič, Anna Panovska, Renata Urbanova, Daniel Lysak, Evelyne Callet-Bauchu, Emmanuel Bachy, Lucile Baseggio, Emmanuelle Ferrant, Joris Diels, Jedelyn Cabrieto, Lasse Nielsen, Gilles Salles

Blood (2021) 138 (Supplement 1): 4679.

DOI: https://doi.org/10.1182/blood-2021-147927

Published: 2021

Journal Articles

A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry

Blood (2021) 138 (Supplement 1): 92.

DOI: https://doi.org/10.1182/blood-2021-150721

Published: 2021

Journal Articles

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Blood (2021) 138 (Supplement 1): 93.

DOI: https://doi.org/10.1182/blood-2021-148473

Published: 2021

Journal Articles

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 32–33.

DOI: https://doi.org/10.1182/blood-2020-134440

Published: 2020

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Carmelo Carlo-Stella, MD, Emmanuel Bachy, MD PhD, Fritz C. Offner, MD PhD, Franck Morschhauser, MD PhD, Michael Crump, Gloria Iacoboni, MD, Anna Sureda Balari, MD PhD, Joaquin Martinez-Lopez, MD, Linda Lundberg, Mark Dixon, David Perez Callejo, James Relf, David Carlile, Emily Piccione, Kathryn Humphrey, Michael Dickinson, DMed Sci

Blood (2020) 136 (Supplement 1): 46–48.

DOI: https://doi.org/10.1182/blood-2020-136044

Published: 2020

2 3

NARROW

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Chromatin Accessibility Profiling to Increase Diagnostic Accuracy and Refine Cell-of-Origin Classification of Mature T-Cell Lymphomas

Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry

Single-Agent Ibrutinib Versus Real-World (RW) Treatments for Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Adjusted Comparison of Resonate-2™ with the Cllear and Lyon-Sud Rw Databases

A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only